固態腫瘤治療市場規模、佔有率、成長分析（按治療類型、癌症適應症、最終用戶和地區）—2025 年至 2032 年產業預測

全球固態腫瘤治療市場預計將在 2023 年達到 1,770.6 億美元，從 2024 年的 1915.8 億美元成長到 2032 年的 3,598.9 億美元，在預測期內（2025-2032 年）的複合年成長率達到 8.20%。

由於人口老化和生活方式改變導致癌症風險因素增加，乳癌、肺癌、大腸癌和攝護腺癌等癌症病例不斷增加，全球固態腫瘤治療市場正在擴大。對有效治療方法的需求推動著標靶治療和免疫療法等先進治療方法作為傳統化療的替代方案的應用。越來越多的癌症治療方法，加上監管機構對新型療法的穩定核准，進一步推動了市場成長。透過生物標記和基因組分析增加對個人化醫療的研發投資也值得注意。醫療支出增加、新興經濟體醫療可近性的改善以及對基於價值的照護的關注等因素，正在推動全球採用創新固體癌療法。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與約束

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 顧客購買行為分析

固態腫瘤藥物市場規模（依治療類型和複合年成長率） (2025-2032)

• 市場概覽
• 化療
• 標靶治療
• 免疫療法
• 荷爾蒙療法
• 其他

固態腫瘤藥物市場規模（依癌症適應症和複合年成長率） (2025-2032)

• 市場概覽
• 乳癌
• 肺癌
• 大腸直腸癌
• 攝護腺癌
• 肝癌
• 其他

固態腫瘤藥物市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概覽
• 醫院
• 癌症研究中心
• 專科診所

固態腫瘤藥物市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 按部門分類的公司佔有率分析
  • 收益同比對比（2022-2024 年）

主要企業簡介

• Roche Holding AG（Switzerland）
• Novartis AG（Switzerland）
• AstraZeneca plc（United Kingdom）
• Bristol Myers Squibb Company（USA）
• Merck & Co., Inc.（USA）
• Pfizer Inc.（USA）
• Amgen Inc.（USA）
• Eli Lilly and Company（USA）
• Johnson & Johnson（USA）
• AbbVie Inc.（USA）
• Sanofi SA（France）
• Bayer AG（Germany）
• Takeda Pharmaceutical Company Limited（Japan）
• Gritstone Bio, Inc.（USA）
• Black Diamond Therapeutics, Inc.（USA）

結論和建議

Global Solid Tumor Therapeutics Market size was valued at USD 177.06 Billion in 2023 and is poised to grow from USD 191.58 Billion in 2024 to USD 359.89 Billion by 2032, growing at a CAGR of 8.20% in the forecast period (2025-2032).

The global solid tumor therapeutics market is expanding due to a rise in cancer cases like breast, lung, colorectal, and prostate cancers, fueled by aging populations and lifestyle changes that increase cancer risk factors. The demand for effective therapies is prompting the adoption of advanced treatment options, including targeted therapies and immunotherapies, as alternatives to traditional chemotherapy. An influx of regulatory approvals for new therapies and a robust oncology drug pipeline are further stimulating market growth. Increased investment in R&D for personalized medicine, driven by biomarkers and genomic profiling, is also noteworthy. Contributing factors such as rising healthcare spending, improved access in emerging economies, and the focus on value-based care are facilitating greater adoption of innovative solid tumor therapies worldwide.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Solid Tumor Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Solid Tumor Therapeutics Market Segments Analysis

The global solid tumour therapeutics market is segmented based on therapy type, cancer indication, end user, and region. In terms of therapy type, the market is divided into chemotherapy, targeted therapy, immunotherapy, hormone therapy, and others. Based on cancer indication, the market is categorized into breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, and others. Based on end user, the market is segmented into hospitals, cancer research centers, and specialty clinics. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Driver of the Global Solid Tumor Therapeutics Market

One of the key market drivers for the global solid tumor therapeutics market is the increasing prevalence of solid tumors due to rising risk factors such as aging populations, unhealthy lifestyle choices, and environmental influences. As the incidence of various solid tumors, including breast, lung, and colorectal cancers, continues to escalate, there is a growing demand for effective therapeutic options. Additionally, advancements in cancer research and technology have facilitated the development of targeted therapies and immunotherapies, providing more effective treatment modalities. This convergence of rising patient needs and innovative treatment approaches is significantly propelling market growth.

Restraints in the Global Solid Tumor Therapeutics Market

One significant market restraint for the global solid tumor therapeutics market is the high cost associated with the development and commercialization of innovative treatments. The complex nature of solid tumors often necessitates extensive research and clinical trials, which can lead to substantial financial investments. This economic burden can limit access for patients, particularly in developing regions, and may deter both pharmaceutical companies and investors from pursuing new therapies. Additionally, stringent regulatory requirements can further complicate the approval process, causing delays and increasing overall development costs, thereby hindering the growth potential of the market.

Market Trends of the Global Solid Tumor Therapeutics Market

The global solid tumor therapeutics market is witnessing a significant trend towards the integration of AI and digital pathology for enhanced treatment personalization. These technological advancements are revolutionizing tumor characterization, enabling oncologists to develop tailored treatment plans that are more effective and efficient. By leveraging AI-powered diagnostics, healthcare providers can improve patient outcomes through greater predictability of results. This shift is driving the broader adoption of precision medicine, allowing for targeted therapies that cater to the unique genetic profiles of various cancers. As a result, the market is becoming increasingly focused on innovative, data-driven approaches to solid tumor treatment.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Solid Tumor Therapeutics Market Size by Therapy Types & CAGR (2025-2032)

• Market Overview
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Hormone Therapy
• Others

Global Solid Tumor Therapeutics Market Size by Cancer Indication & CAGR (2025-2032)

• Market Overview
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Others

Global Solid Tumor Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Cancer Research Centers
• Specialty Clinics

Global Solid Tumor Therapeutics Market Size & CAGR (2025-2032)

• North America (Therapy Types, Cancer Indication, End User)
  • US
  • Canada
• Europe (Therapy Types, Cancer Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Types, Cancer Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Types, Cancer Indication, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Types, Cancer Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gritstone Bio, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Black Diamond Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations